As per Lipinski's rule, the parameters for the drug-like property for the ligands have been listed and compared Figure 1. The first four commercial drugs have a higher molecular weight by not obeying the rule. Afinitor, Lapatinib, Letrozole and Palbociclib show higher donor HB and hence do not obey the rule. The first four and Palbociclib show a negative red band indicating their non-drug like behavior. Surprisingly, except Stigmasterol all the others show a positive drug-like property of QlogPo/w. In the Overall sense, Rule of Five shows a non-drug like nature for the first four commercial drugs. PSA is negative for Afinitor. Likewise, QPlog BB shows the same trend. The ADME properties, Qplog HERG, QPP Caco and QPPMDCK show a nondrug like nature for all the ligands except Raloxifene, Tamoxifen, Stigmasterol and Oleic acid. Thus, the comparison of the ligands based on the Lipinski's rule and ADME properties indicate a strong drug likeness for the best commercial drugs Raloxifene and Tamoxifen that have been observed with the green blocks for all the properties in the tabular diagram, Figure 1. Coincidently, the isolated compounds, Stigmasterol and Oleic acid show the same nature as these two commercial drugs and expected to behave in the same manner as the drug like molecules. This would be evaluated by the in-silico method by the interaction studies with the target, as discussed in the following section.